Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597190 | 0.83 | HAO1 (0.44) | MAPTALDH1A1HAO1 | |
| SCHEMBL4596513 | 0.81 | MAOA (0.44) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL4596529 | 0.81 | TYMS (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4597157 | 0.78 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3805487 | 0.78 | PTGIR (0.41) | SMN1; SMN2TP53MAPTALDH1A1HPGD | |
| SCHEMBL4596630 | 0.78 | CYP26A1 (0.40) | TP53ALDH1A1HPGDHTT | |
| SCHEMBL4596641 | 0.77 | MAPT (0.34) | SMN1; SMN2TP53MAPTALDH1A1NOTUM | |
| SCHEMBL4596971 | 0.75 | CYP4F2 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4598185 | 0.75 | NR4A1 (0.41) | SMN1; SMN2TP53MAPTALDH1A1HPGD | |
| SCHEMBL5573786 | 0.75 | ABCG2 (0.37) | TP53MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | NPC1 473/4885RAB9A 2707/4885SMN1; SMN2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.